JP2021517128A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021517128A5 JP2021517128A5 JP2020546876A JP2020546876A JP2021517128A5 JP 2021517128 A5 JP2021517128 A5 JP 2021517128A5 JP 2020546876 A JP2020546876 A JP 2020546876A JP 2020546876 A JP2020546876 A JP 2020546876A JP 2021517128 A5 JP2021517128 A5 JP 2021517128A5
- Authority
- JP
- Japan
- Prior art keywords
- levodopa
- carbidopa
- secant
- top layer
- therapeutic agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 claims 34
- 229960004502 levodopa Drugs 0.000 claims 34
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 claims 33
- 229960004205 carbidopa Drugs 0.000 claims 17
- TZFNLOMSOLWIDK-JTQLQIEISA-N carbidopa (anhydrous) Chemical compound NN[C@@](C(O)=O)(C)CC1=CC=C(O)C(O)=C1 TZFNLOMSOLWIDK-JTQLQIEISA-N 0.000 claims 17
- 239000003814 drug Substances 0.000 claims 16
- 229940124597 therapeutic agent Drugs 0.000 claims 16
- IVTMXOXVAHXCHI-YXLMWLKOSA-N (2s)-2-amino-3-(3,4-dihydroxyphenyl)propanoic acid;(2s)-3-(3,4-dihydroxyphenyl)-2-hydrazinyl-2-methylpropanoic acid Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1.NN[C@@](C(O)=O)(C)CC1=CC=C(O)C(O)=C1 IVTMXOXVAHXCHI-YXLMWLKOSA-N 0.000 claims 9
- 229940052036 carbidopa / levodopa Drugs 0.000 claims 7
- 239000003937 drug carrier Substances 0.000 claims 6
- 208000018737 Parkinson disease Diseases 0.000 claims 5
- 239000003795 chemical substances by application Substances 0.000 claims 5
- 238000001990 intravenous administration Methods 0.000 claims 5
- 230000001225 therapeutic effect Effects 0.000 claims 5
- 239000004480 active ingredient Substances 0.000 claims 4
- 229940015929 carbidopa 12.5 mg Drugs 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 230000004044 response Effects 0.000 claims 4
- 241000255925 Diptera Species 0.000 claims 2
- 230000036470 plasma concentration Effects 0.000 claims 2
- 208000014094 Dystonic disease Diseases 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- 208000010118 dystonia Diseases 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 claims 1
- 229940067290 levodopa 50 mg Drugs 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 230000004043 responsiveness Effects 0.000 claims 1
- 238000011272 standard treatment Methods 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022110134A JP2022133449A (ja) | 2018-03-29 | 2022-07-08 | レボドパ分割用量組成物および使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862650012P | 2018-03-29 | 2018-03-29 | |
| US62/650,012 | 2018-03-29 | ||
| PCT/US2019/024464 WO2019191353A1 (en) | 2018-03-29 | 2019-03-28 | Levodopa fractionated dose composition and use |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022110134A Division JP2022133449A (ja) | 2018-03-29 | 2022-07-08 | レボドパ分割用量組成物および使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021517128A JP2021517128A (ja) | 2021-07-15 |
| JP2021517128A5 true JP2021517128A5 (https=) | 2021-08-26 |
Family
ID=68060752
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020546876A Pending JP2021517128A (ja) | 2018-03-29 | 2019-03-28 | レボドパ分割用量組成物および使用 |
| JP2022110134A Pending JP2022133449A (ja) | 2018-03-29 | 2022-07-08 | レボドパ分割用量組成物および使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022110134A Pending JP2022133449A (ja) | 2018-03-29 | 2022-07-08 | レボドパ分割用量組成物および使用 |
Country Status (6)
| Country | Link |
|---|---|
| US (3) | US11033521B2 (https=) |
| EP (1) | EP3773532A4 (https=) |
| JP (2) | JP2021517128A (https=) |
| CN (1) | CN111954523A (https=) |
| BR (1) | BR112020017422A2 (https=) |
| WO (1) | WO2019191353A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3773532A4 (en) * | 2018-03-29 | 2022-11-02 | Avion Pharmaceuticals, LLC | FRACTIONAL LEVODOPA DOSAGE AND USE |
| WO2022044045A1 (en) * | 2020-08-26 | 2022-03-03 | Rubicon Research Private Limited | Modified release formulations of levodopa |
| GB2644236A (en) * | 2024-09-24 | 2026-03-25 | Novumgen Ltd | Orodispersible tablet composition containing carbidopa and levodopa |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5061494A (en) * | 1990-06-14 | 1991-10-29 | The Upjohn Comany | Tri-scored drug tablet |
| ES2385832T3 (es) | 2004-05-21 | 2012-08-01 | Accu-Break Technologies, Inc. | Comprimidos farmacéuticos que presentan un segmento relativamente inactivo |
| US7838031B2 (en) | 2004-05-21 | 2010-11-23 | Lawrence Solomon | Method of administering a partial dose using a segmented pharmaceutical tablet |
| CN1960713A (zh) * | 2004-05-21 | 2007-05-09 | 阿库-伯雷克技术公司 | 含有两个或多个单元片段的药片 |
| US8506999B2 (en) | 2005-05-23 | 2013-08-13 | Accu-Break Technologies, Inc. | Pharmaceutical tablets comprising a plurality of segments |
| US20070275060A1 (en) * | 2005-08-05 | 2007-11-29 | Osmotica Costa Rica Sociedad Anonima | Extended release solid pharmaceutical composition containing carbidopa and levodopa |
| US8231902B2 (en) | 2005-11-18 | 2012-07-31 | Accu-Break Technologies, Inc. | Segmented pharmaceutical dosage forms |
| RU2484815C2 (ru) * | 2006-05-31 | 2013-06-20 | Зольвай Фармасьютиклз Гмбх | Продолжительное 24-часовое введение в кишечник леводопа/карбидопа |
| US20080131492A1 (en) * | 2006-06-23 | 2008-06-05 | Spherics, Inc. | Dosage forms for movement disorder treatment |
| RU2540465C2 (ru) * | 2008-08-22 | 2015-02-10 | Вокхардт Рисерч Сентер | Фармацевтическая композиция энтакапона или его солей пролонгрированного высвобождения |
| WO2010134074A1 (en) * | 2009-05-19 | 2010-11-25 | Neuroderm Ltd | Compositions for continuous administration of dopa decarboxylase inhibitors |
| PT2968218T (pt) * | 2013-03-13 | 2021-09-24 | Neuroderm Ltd | Combinação para tratamento da doença de parkinson |
| MX2015013624A (es) * | 2013-03-28 | 2016-06-10 | Omniactive Health Technologies Ltd | Efecto neuroprotector de carotenoides en el cerebro. |
| JP2018500300A (ja) * | 2014-11-28 | 2018-01-11 | ノヴィファーマ，エス．アー． | パーキンソン病を遅延させるための医薬 |
| ES2895054T3 (es) * | 2016-08-18 | 2022-02-17 | Ilko Ilac Sanayi Ve Ticaret Anonim Sirketi | Fórmula de comprimido antiparkinson con perfil de disolución mejorado |
| EP3773532A4 (en) * | 2018-03-29 | 2022-11-02 | Avion Pharmaceuticals, LLC | FRACTIONAL LEVODOPA DOSAGE AND USE |
-
2019
- 2019-03-28 EP EP19775769.3A patent/EP3773532A4/en not_active Withdrawn
- 2019-03-28 CN CN201980023074.8A patent/CN111954523A/zh active Pending
- 2019-03-28 BR BR112020017422-0A patent/BR112020017422A2/pt unknown
- 2019-03-28 WO PCT/US2019/024464 patent/WO2019191353A1/en not_active Ceased
- 2019-03-28 JP JP2020546876A patent/JP2021517128A/ja active Pending
- 2019-12-18 US US16/719,203 patent/US11033521B2/en active Active
-
2021
- 2021-03-31 US US17/219,253 patent/US11439613B2/en active Active
-
2022
- 2022-07-08 JP JP2022110134A patent/JP2022133449A/ja active Pending
- 2022-08-26 US US17/896,808 patent/US11819485B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7442095B2 (ja) | ベータ－ヒドロキシブチレート及びブタンジオールのｓ－エナンチオマー並びにその使用方法 | |
| Schapira et al. | Study on the effects of tablet colour in the treatment of anxiety states | |
| ES2214729T3 (es) | Acido 9-cis-retinoico para enfermedades inmunes inducidas por celulas. | |
| JP2023040166A (ja) | カンナビジオールによる脆弱ｘ症候群の処置 | |
| Rigante et al. | The pharmacologic basis of treatment with colchicine in children with familial Mediterranean fever | |
| WO2005065069A3 (en) | Pharmaceutical methods, dosing regimes and dosage forms for the treatment of alzheimer's disease | |
| AU2310200A (en) | Pharmaceutical compositions | |
| HUE035105T2 (en) | A composition comprising nicotine and opipramole and its use | |
| CN106999467A (zh) | 治疗认知减退的方法 | |
| US11826321B2 (en) | Cyclobenzaprine treatment for agitation, psychosis and cognitive decline in dementia and neurodegenerative conditions | |
| JP7429942B2 (ja) | テトラヒドロ－ｎ，ｎ－ジメチル－２，２－ジフェニル－３－フランメタンアミン（ａｎａｖｅｘ２－７３）のエナンチオマーならびにシグマ１レセプターにより調節されるアルツハイマー型および他の傷害の処置におけるその使用 | |
| JP2021517128A5 (https=) | ||
| EP4661867A1 (en) | Compositions comprising n,n-dimethyltryptamine, optionally in combination with n-acylethanolamines and uses thereof | |
| JP2016505050A5 (https=) | ||
| ES2677474T3 (es) | Un metabolito de iloperidona para uso en el tratamiento de trastornos psiquiátricos | |
| US20250302773A1 (en) | Compositions comprising meai and n-acylethanolamines and uses thereof | |
| JP2011121975A (ja) | 線維筋痛症に伴う疼痛を改善するための線維筋痛症に伴う疼痛改善用医薬組成物 | |
| CN120659608A (zh) | 用于治疗癌症的tead抑制剂和kras g12d抑制剂组合 | |
| CA2990880A1 (en) | Thromboxane receptor antagonists in aerd/asthma | |
| Bourde et al. | Controlled Clinical Trial Of An Antiaggregating Agent, Ti-Clopidine, In Vascular Ulcers Of The Leg | |
| FR2647784A1 (fr) | Association de vitamine a a dose physiologique et de differents principes actifs ayant une activite therapeutique | |
| CN104906501A (zh) | 治疗银屑病的中药组分组合物 | |
| US11826326B2 (en) | Benzoic acid or a salt and derivative thereof for use in preventing or treating depression | |
| CN108478581A (zh) | 防治运动病、梅尼埃病的药物及托伐普坦的医药用途 | |
| JPWO2022064387A5 (https=) |